Cardiff Oncology Inc - Company Profile
Powered by 
All the sales intelligence you need on Cardiff Oncology Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cardiff Oncology Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cardiff Oncology Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cardiff Oncology Inc (Cardiff) is a clinical-stage biotechnology company focused on developing novel cancer therapies. The company's main activity involves leveraging PLK1 inhibition to create treatments for various cancers with significant unmet medical needs. Its major product is onvansertib, an oral and highly selective PLK1 inhibitor, which is being developed in combination with standard-of-care therapeutics. Cardiff is advancing various clinical trials, including the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC) and the TROV-054 trial for second-line KRAS-mutated mCRC. The company utilizes tumor genomics and biomarker assays to enhance patient response assessments. It is also investigating onvansertib for metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer, exploring various combination therapies. Cardiff is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11055 Flintkote Avenue, San Diego, California, 92121
Website
cardiffoncology.com
Telephone
1 858 9527570
No of Employees
31
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRDF (NASD)
Revenue (2024)
$593,000
-13.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-0.9%
(2024 vs 2023)
Market Cap*
$76.6M
Net Profit Margin (2024)
XYZ
-16.2%
(2024 vs 2023)
* As of and is in US$
Cardiff Oncology Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Onvansertib |
Competitor Comparison
| Key Parameters | Cardiff Oncology Inc | Boehringer Ingelheim International GmbH | Jazz Pharmaceuticals Plc | Genetix Biotherapeutics Inc | Coherus Oncology Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | Ireland | United States of America | United States of America |
| City | San Diego | Ingelheim am Rhein | Dublin | Somerville | Redwood City |
| State/Province | California | Rheinland-Pfalz | Dublin | Massachusetts | California |
| No. of Employees | 31 | 54,300 | 2,890 | 248 | 144 |
| Entity Type | Public | Private | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rodney S. Markin, M.D., Ph.D. | Chairman | Executive Board | 2020 | 74 |
| Josh Muntner | Chief Financial Officer | Senior Management | 2026 | - |
| Brigitte Lindsay | Chief Accounting Officer | Senior Management | 2026 | - |
| Roger Sidhu, MD | Chief Medical Officer | Senior Management | 2025 | - |
| Tod Smeal, Ph.D. | Chief Scientific Officer | Senior Management | 2022 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer